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HDAC inhibitors can regulate gene expression by post-translational modification of histone as well as nonhistone pro-
teins. Often studied at single loci, increased histone acetylation is the paradigmatic mechanism of action. However, little is
known of the extent of genome-wide changes in cells stimulated by the hydroxamic acids, TSA and SAHA. In this article,
we map vascular chromatin modifications including histone H3 acetylation of lysine 9 and 14 (H3K9/14ac) using chro-
matin immunoprecipitation (ChIP) coupled with massive parallel sequencing (ChIP-seq). Since acetylation-mediated gene
expression is often associated with modification of other lysine residues, we also examined H3K4me3 and H3K9me3 as
well as changes in CpG methylation (CpG-seq). RNA sequencing indicates the differential expression of ~30% of genes,
with almost equal numbers being up- and down-regulated. We observed broad deacetylation and gene expression changes
conferred by TSA and SAHA mediated by the loss of EP300/CREBBP binding at multiple gene promoters. This study
provides an important framework for HDAC inhibitor function in vascular biology and a comprehensive description of
genome-wide deacetylation by pharmacological HDAC inhibition.
[Supplemental material is available for this article.]
Histone acetylation is regulated by the opposing actions of his-
tone acetyltransferases (HAT) and histone deacetylases (HDAC)
(Marks and Xu 2009; Marks 2010). HATs catalyze the addition of
acetyl groups to the e-amino group of lysine residues of core his-
tones, neutralizing their positive charge. This results in aweakened
interaction with the negatively charged DNA, effecting a more
open, transcriptionally active, chromatin conformation (Roth et al.
2001; Smith and Denu 2009). Conversely, HDACs catalyze the re-
moval of acetyl groups from lysine residues, resulting in a more
compact, transcriptionally repressive state (Kuo and Allis 1998;
Dokmanovic et al. 2007). There are 18mammalianHDACs classified
on the basis of their homology with yeast proteins (de Ruijter
et al. 2003). Class I (HDAC1, HDAC2, HDAC3, and HDAC8) is pre-
dominantly localized in the nucleus with ubiquitous tissue distribu-
tion (de Ruijter et al. 2003; Gregoretti et al. 2004). Class II HDACs are
further divided into IIa (HDAC4, HDAC5, HDAC7, and HDAC9) and
IIb (HDAC6 and HDAC10) and shuttle between the cytoplasm and
nucleuswith restricted tissue distribution (Marks andXu2009;Marks
2010). The only member of class IV is HDAC11, which shares simi-
larity with both class I and II enzymes (de Ruijter et al. 2003). The
other HDAC enzymes, known as the sirtuins (SIRT1–7), are homol-
ogous to the yeast enzyme silent information regulator 2 (Landry
et al. 2000; Tanner et al. 2000). These are nicotinamide adenine
dinucleotide (NAD+)-dependent enzymes, which deacetylate lysine
residues by consumingNAD+ (Landry et al. 2000; Tanner et al. 2000).
The current paradigm suggests that HDAC inhibition in-
creases acetylation of core histones resulting in altered gene ex-
pression (Bolden et al. 2006). The current molecular mechanisms
that regulate gene expression in mammalian cells are derived
mainly from experiments designed to explore parallels between
HDAC inhibition and lysine modification (Minucci and Pelicci
2006). HDAC inhibitors are also known to interact with nonhistone
substrates, including transcription factors and coregulators, chap-
erones, signaling and motility mediators, as well as DNA repair
proteins (Marks and Xu 2009;Marks 2010). It is clear that we do not
have a complete understanding of the regulatory activities of
HDACs, of which several well-characterized inhibitors function to
modify lysine residues and regulate gene expression. Because the
mechanisms of the HDAC inhibitor action are complicated, it is
important that we have a better understanding of the pharmaco-
logical action, given the interest in developing these compounds as
therapeutic agents (Marks and Breslow 2007). Recently, two HDAC
inhibitors, SAHA (suberoylanilide hydroxamic acid; also known as
vorinostat and Zolinza) and depsipeptide (romidepsin, Istodax)
were approved by the US FDA (Thaler and Minucci 2011). The
chemical structure of SAHA is very similar to that of trichostatin A
(TSA), which predominantly inhibits Class I and II HDAC enzymes.
The mechanism of action is thought to involve gene-activation
events conferred by increased lysine acetylation.
More than just an inner lining of blood vessels, the vascular
endothelium serves as an autocrine and paracrine organ regulating
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diverse processes in all vascularized tissues, including vascular per-
meability, angiogenesis, and the recruitment of inflammatory cells.
Critical to maintaining homeostatic vascular function, endothelial
cells that line the cardiovascular system are the interface between
inflammation and the vessel wall and play a key role in sensing
changes in blood-borne stimuli and transmitting signaling events to
the underlying layers of the vessel. Endothelial dysfunction is strongly
linked with inflammation in diabetes and cardiovascular disease, and
the activated endothelial cell has, accordingly, emerged as a thera-
peutic target (Hirase and Node 2012). Identification of the multitude
of transcript-codinggenes potentially impactedbyHDAC inhibition is
paramount to a comprehensive understanding of histone acetylation
andgeneexpression inendothelial aswell as other cell types. The rapid
emergence and increased accessibility of high-throughput sequencing
technologies that facilitate genome and transcriptome-wide analysis
has driven the generation and accumulation of large repositories of
publicly accessible data. Integration of these and experimentally
generated data sets greatly enhances our ability to interrogate cellular
responses to HDAC inhibition. In this study, the results of a genome-
widemapof chromatinmodifications in vascular endothelial cells are
presented for the hydroxamic acids, TSA and SAHA. Our results, de-
rived from 1.3 billion sequence reads, indicate gene expression
changes subject to histone acetylation and deacetylation events.
Results
Anti-inflammatory response by HDAC inhibition
Inflammatory processes are central to cardiovascular and endo-
thelial cell dysfunction (Pober and Sessa 2007). In primary human
aortic endothelial cells (HAECs), TSA reduced (>75%) LPS-induced
monocyte adhesion (Supplemental Fig. 1A). Phorbol myristate
acetate (PMA) increased the production of endothelial reactive
oxygen species (ROS), which is associated with stimulating mono-
cyte adhesion. TSA reduced PMA-induced ROS overproduction
(Supplemental Fig. 1B), as well as the expression of genes associated
with tumor necrosis factor (TNF) signaling (Supplemental Fig. 1C).
We observed reduced TNF-dependent IL8, CCL2, and VCAM1 gene
expression in TSA-stimulated HAECs (Supplemental Fig. 1D). Con-
sistent with changes in gene expression, TSA attenuated chemokine
and cytokine release,with a strong reductionof twohighly expressed
inflammatory proteins, CCL2 and IL6 (Supplemental Fig. 1E). Dose-
dependent accumulation of acetylation of lysines 9 and 14 on his-
tone 3 (H3K9/14ac) was also observed (Supplemental Fig. 2A). TSA
increasedH3K4me3 and to a lesser extentH3K4me1 andH3K4me2.
Quantitation shows the dose-dependent nature of TSA-induced in-
creases in H3K9/14ac and H3K4me3 (Supplemental Fig. 2B). MTS
and crystal violet cytotoxicity assays showTSA-stimulation does not
significantly change cell viability at 12 h (Supplemental Fig. 2C).
These results suggest HDAC inhibition confers anti-inflammatory
responses in primary HAECs.
Genome-wide maps reveal extensive deacetylation by HDAC
inhibition
While TSA is associated with histone acetylation and gene ex-
pression (Sheridan et al. 1997), more recent studies have shown
localized deacetylation by sodium butyrate (Rada-Iglesias et al.
2007). To investigate genome-wide changes conferred by TSA, we
generated histonemodification and DNAmethylationmaps using
ChIP-seq and CpG-seq approaches, respectively. We also integrated
chromatin modifications with gene expression (mRNA-seq). To do
this, we developed a method to analyze the differential distribu-
tion of sequenced tags using MACS software with a P = 105 cut-
off (Zhang et al. 2008). Stimulated HAECs were compared to
unstimulated native cells using edgeR (Robinson et al. 2010).
Statistical significance was based on the Benjamini-Hochberg
adjusted P-value < 0.05 (Benjamini and Hochberg 1995). We ob-
served important details about the regions of the vascular endo-
thelial genome subject to HDAC inhibition. Increased histone
acetylation was often enriched at sites with low acetylation levels
before TSA stimulation (Fig. 1A). This is seen in the clustering of
regions with increased acetylation with low abundance reads
(upper-left quadrant). In contrast, reduced acetylation was clearly
observed in the lower-right quadrant, indicating the genome is
also subject to broad histone deacetylation at regions previously
hyperacetylated (high tag counts), which is clearly evident by
chromosome ideogram (Supplemental Fig. 2D). The number of
increased and reduced H3K9/14ac regions was comparable at
22,761 acetylated sites versus 23,961 deacetylated sites (adjusted
P < 0.05) (Fig. 1B). Compared to H3K9/14 acetylation, we found a
small but significant increase in H3K4me3 (2638 versus 491)
(Supplemental Table 1).We did not observe significant changes in
H3K9me3 and DNA methylation, consistent with recent obser-
vations (Raynal et al. 2012). Collectively, our data indicate dis-
tinguishable acetylation and deacetylation signals in response to
pharmacological HDAC inhibition.
Diverse changes conferred by HDAC inhibition
The transcription start site (TSS) is an integral element of gene
regulation, and while the position of promoters in the genome can
vary considerably, proximal TSS sequences are considered impor-
tant sites of gene regulation (Raney et al. 2011). Since H3K9/14ac
is functionally associated with gene promoters, we examined
uniquely mapped tags at the TSS. Unless otherwise specified, we
define promoter regions as 2.5 kb up- and downstream of the TSS.
As shown in Figure 1C, histone deacetylation was prominent at
gene promoters (deacetylation 44% versus acetylation 6%). Since
changes in H3K9/14ac might be more widespread, we examined
the distribution ofH3K9/14ac by dividing the human genome into
the proximal promoter, promoter with CpG islands (CGI), coding
exons, exons, introns, 39 UTR, 59 UTR, and CpG islands, as well as
intergenic regions and the whole gene. These regions were anno-
tated using the UCSC Genome Browser (Kent et al. 2002) and
expressed as the odds ratio (log to the base of 2, log2) of the ob-
served differences compared to nondifferential acetylated regions.
Deacetylated regions were more likely to be found in the proximal
promoter (with and without CGI), exons, and 59 UTR, as well as
CGI regions of genes in vascular endothelial cells (Fig. 1D). While
changes in H3K4me3 were more evenly distributed between ge-
nomic features, this was less likely to occur at intergenic sites (data
not shown). There were no statistically significant changes in DNA
methylation or H3K9me3. Further analysis revealed histone
deacetylation changes associated with mRNA and noncoding
RNA (ncRNA). We found significant changes at genes that code for
ncRNAs (Fig. 1E).While both increased and reduced acetylation was
found at long ncRNA (lncRNA), deacetylation was prominent for
tRNAs, miRNAs, and snoRNAs.
Genomic methylation content defines regionalized changes
Mammalian promoters exhibit variable CG content (Blanchette
et al. 2006) and promoter regions of high CG content and
1272 Genome Research
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are associated with CpG islands. These high-CpG content
promoters (HCP) are associated with ubiquitously expressed
genes (Mikkelsen et al. 2007). In contrast, low-CpG content
promoters (LCP) are distinguishable by selective histone modi-
fications associated with gene expression. In TSA-stimulated
cells, H3K9/14ac signals were often sheltered by DNA methyla-
tion at sites of increased (Supplemental Fig. 3A) or reduced
(Supplemental Fig. 3B) histone acetylation. Because genomic
methylation is generally reported to inversely correlate with
gene expression, we examined the TSA response by dividing our
analysis of the promoter regions of low (LCP, n = 18,946 regions)
and high (HCP, n = 2588 regions) CpG methylation content.
Fisher’s exact test was used to determine the relationship be-
tween differential gene expression and H3K9/14ac changes at
methylated promoters, and the results are expressed as the odds
ratio (log2) with 95% confidence intervals. We show that in-
creased gene expression was more likely to occur at HCPs (Fig.
2A), and reduced expression was less likely to occur at promoters
with HCPs. With respect to histone modification, TSA-stimu-
lated changes in H3K9/14ac (both increases and decreases) were
less likely to occur at HCP sites (Fig. 2B). This is in striking con-
trast to LCP regions that were more likely to exhibit changes in
H3K9/14ac. These results suggest that TSA stimulation was more
likely to change H3K9/14ac at LCP sites, whereas HCPs are
enriched for increased changes in gene expression.
Differential chromatin modifications associated with gene
expression
Next we determined if histone modifications at promoters were
associated with changes in gene expression using Fisher’s exact
test (Table 1). Reduced gene expression was more likely to occur
with decreased H3K9/14ac and H3K4me3 with odds ratios of 2.47
and 3.41, respectively, whereas up-regulated genes were more
likely to be associated with increased H3K9/14ac and H3K4me3
with odds ratios of 4.80 and 6.59, respectively. We then sought to
determine whether histone modification change was correlated
with gene expression. We found that 80% of the top 320 most
up-regulated genes were associated with increased H3K9/14ac at
the gene promoter (Fig. 2C), compared to only 20% of all up-
regulated genes. This compares with <10% of genes with an in-
crease in H3K9/14ac with no change in gene expression. These
results suggest genes exhibiting large increases in gene expression
were more likely to be enriched for acetylation. Given this re-
lationship, we also examined the association with reduced gene
expression. We found 90% of all down-regulated genes were
Figure 1. Biological effects of TSA in primary human vascular endothelial cells. (A) Genome-wide distribution of chromatin marks shows significant
H3K9/14 acetylation and deacetylation by HDAC inhibition. The plots shown compare the number of tags (the log2 of the read abundance, i.e.,
logConcentration determined by edgeR) versus the log2 fold change (log2FC). Regions subject to significant changes are shown in red (adjusted P < 0.05),
and nonsignificant changes are shown in black for TSA-stimulated HAECs. Distribution plots were divided into four quadrants for H3K9/14ac and
H3K4me3. (B) The number of differential H3K9/14ac regions (adjusted P < 0.05). Determination of differential enrichment is described in theMethods. (C )
The percentage of differential H3K9/14ac regions (adjusted P < 0.05) located within the gene promoter (2.5 kb either side of the TSS). Enrichment of
H3K9/14ac by genomic feature (D) and mRNA/ncRNA (E) was determined using Fisher’s exact test. The log2 odds ratio for the genomic distribution of
increased and decreased H3K9/14ac is represented. Error bars represent 95% confidence intervals.
Deacetylation by HDAC inhibition
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associated with deacetylation, including genes that do not change
in expression (Fig. 2D).
HDAC inhibition is broadly associated with increased gene
expression.We show that 27% of genes are differentially regulated
by TSA, and we observed comparable numbers of down- (12.6%)
and up- (14.5%) regulated transcripts using mRNA-seq (Supple-
mental Fig. 4A). Integration of promoter specific changes in H3K9/
14ac and H3K4me3 with changes in gene expression identified
numerous significant associations (Table 2). While 12 genes were
associated with bivalent marks and reduced gene expression, we
found 583 genes were correlated with increased H3K9/14ac and
H3K4me3. Our data also revealed key genes relevant to the endo-
thelium, including those relevant to angiogenesis and inflamma-
tion as well as to changes in chemokine- and cytokine-related
signaling (Table 3). Quantification of 20 genes associated with
chemokine and cytokine response as well as endothelial function
confirmed the close association between qRT-PCR and mRNA-
seq (Supplemental Fig. 4B). Furthermore, ChIP-seq signals for
histone acetylation were validated using qRT-PCR (Supplemental
Fig. 4C).
HDAC inhibition alters coregulators of gene transcription
We used gene set enrichment analyses (GSEA) to explore the po-
tential mechanisms of histone deacetylation implicated in gene
transcription (Subramanian et al. 2005). GSEA of mRNA-seq data
sets identified major pathways altered by TSA (Supplemental Table
2). We identified increased expression of gene targets such as the
corepressor REST, as well as those involved with channel activity.
Down-regulated gene sets included those involved with chromatin
and DNA binding as well as cytokine production. These results
suggest that regulatory factors involved in the control of gene
transcription are subject to deacetylation by HDAC inhibition.
Next, we examined mRNA-seq patterns in TSA-stimulated HAECs.
As shown in Table 4, increased expression of HDACs that belong to
Class I (HDAC1 and HDAC3) and Class II (HDAC5), as well as Class
IV (HDAC11), was observed. Interestingly, we also found reduced
Figure 2. DNA methylation is correlated with the action of TSA at gene promoters. Fisher’s exact test was used to correlate gene expression and H3K9/
14ac with DNA methylation. DNA methylation regions with a concentration (log2 of the average number of reads in all samples per region, i.e.,
logConcentration determined by edgeR) of greater than 17 were classified as high levels of methylation (HCP), and regions below 17 were defined as
low DNAmethylation (LCP). Error bars represent 95% confidence intervals of the log2 of the odds ratio. (A) Changes in mRNA expression were defined as
log2FC > 0 (increased gene expression) or log2FC < 0 (decreased gene expression), and adjusted P < 0.05. (B) Regions of acetylationwere defined as log2FC > 1
(increased acetylation) or log2FC < 1 (decreased acetylation), adjusted P < 0.05. Only regions with preexisting histone acetylation (cutoff of 400 reads)
were included in the analyses. Correlations between increased (C ) and decreased (D) gene expression are shown for histone acetylation (yellow) and
deacetylation (green). Genes were grouped (x-axis) according to the level of up- or down-regulation observed from the mRNA-seq analysis, as a cumu-
lative rank (i.e., top 10 genes, top 20 genes, and so on, where the largest ‘‘all’’ category represents the whole gene set and ‘‘nc’’ represents no change,
adjusted P < 0.05). The correlation is reported as the percentage of genes in each rank associated with changes in H3K9/14ac at the promoter.
Table 1. Statistical analyses of histone modification and gene expression in TSA-stimulated HAECs
Histone P-valuea Odds ratiob Decreased mRNA expression
[H3K9/14ac 4.64 3 1045 0.39 Increased H3K9/14ac less likely to occur in down-regulated genes
YH3K9/14ac 9.38 3 1071 2.47 Decreased H3K9/14ac more likely to occur in down-regulated genes
[H3K4me3 9.80 3 10124 0.17 Increased H3K4me3 less likely to occur in down-regulated genes
YH3K4me3 5.20 3 103 3.41 Decreased H3K4me3 more likely to occur in down-regulated genes
Histone P-valuea Odds ratiob Increased mRNA expression
[H3K9/14ac 1.76 3 10218 4.80 Increased H3K9/14ac more likely to occur in up-regulated genes
YH3K9/14ac 3.04 3 10251 0.26 Decreased H3K9/14ac less likely to occur in up-regulated genes
[H3K4me3 0 6.59 Increased H3K4me3 more likely to occur in up-regulated genes
YH3K4me3 3.75 3 102 0.25 Decreased H3K4me3 less likely to occur in up-regulated genes
aCalculated using Fisher’s exact test of differentially regulated genes and histone modification.
bOdds ratio < 1 indicates an inverse correlation.
Rafehi et al .
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expression of HATs, including the functionally and structurally
related CREBBP and EP300 (Liu et al. 2008). Integrated ENCODE
ChIP-seq data sets (Raney et al. 2011) with GSEA revealed deacet-
ylation of genes associated with chromatin and DNA binding
as well as coregulatory factors (Fig. 3A). GSEA revealed a strong
association with EP300 and histone deacetylation at promoters
(Fig. 3B). Based on these results, we hypothesized that gene sup-
pression was subject to reduced HAT binding mediated by TSA. To
test this, we used the EP300/CREBBP-specific inhibitor, C646, to
examine the role of EP300/CREBBP on gene expression (Gao et al.
2013). A protein immunoblot shows that C646 attenuated TSA-
induced histone acetylation (Supplemental Fig. 5). In addition, we
confirm reduced expression of genes such as BMX, PALMD, and
IL6 using the EP300/CREBBP inhibitor C646 (Fig. 3C). We also
note that C646 does not change the expression of several genes.
For example, CCL2 was independent of EP300/CREBBP activity,
whereas the activation of STAC2 and IRS2 was dependent on
EP300/CREBBP inhibition by C646.
Table 2. Changes in chromatin marks associated with gene expression in TSA-stimulated HAECs
Bivalent H3K9/14ac H3K4me3 P-value Odds ratioa
Down-regulated genes (RNA-seq)
Decreased H3K9/14ac 12 4821  4.06 3 103 10.7
Decreased H3K4me3 12   0.14 
Up-regulated genes (RNA-seq)
Increased H3K9/14ac 583 558  5.61 3 1032 8.89
Increased H3K4me3 583  824 1.24 3 106 2.95
Bivalent marks include H3K9/14ac and H3K4me3.
aOdds ratio is the association of bivalent modifications and gene expression change.
Table 3. Endothelial-specific signature in TSA-stimulated cells
Increased gene expression Modification at TSS Description
Gene Accession Adj. P-value FC H3K9/14ac H3K4me3 CpGm Endothelial and other cell functions
STC1 NM_003155 2.59 3 10135 +229.1 [ [ nc Blocks TNF permeability
CRISPLD2 NM_031476 1.48 3 10124 +222.9 [ [ nc LPS-binding protein regulates endotoxin
function
CKB NM_001823 8.15 3 10121 +694.6 [ [ nc Required for thrombin receptor signaling
TNFSF9 NM_003811 3.26 3 10105 +177.3 [ [ nc Cytokine
AQP3 NM_004925 6.51 3 1092 +98.4 [ [ nc Negative regulator of endothelial
differentiation
CELSR2 NM_001408 1.09 3 1064 +46.2 [ [ nc Cadherin/EGF contact mediated
communication
SORT1 NM_002959 3.16 3 1061 +17.5 nc [ nc Cardiovascular risk locus 1p13.3
EFNA3 NM_004952 3.69 3 1060 +41.4 nc [ nc Regulation of angiogenesis and VEGFA
signaling
MAPK8IP1 NM_005456 3.18 3 1059 +36.5 [ [ nc MAPK-pathway, type 2 diabetes candidate
CPA4 NM_001163446 3.68 3 1058 +18.9 [ [ nc Histone hyperacetylation pathway (transcript
variant 2)
DUSP4 NM_004419 1.77 3 1056 +14.4 [ [ nc TNF induced regulation and MAPK-pathway
CPA4 NM_016352 3.97 3 1056 +18.3 [ [ nc Histone hyperacetylation pathway (transcript
variant 1)
H1F0 NM_005318 4.15 3 1055 +13.7 nc [ nc Nucleosome structure
BAIAP2 NM_017450 3.96 3 1052 +28.2 [ [ nc Negative regulator of angiogenesis
Decreased gene expression Modification at TSS Description
Gene Accession Adj. P-value FC H3K9/14ac H3K4me3 CpGm Endothelial and other cell functions
PALMD NM_017734 1.11 3 1094 76.1 Y Y nc Membrane dynamics
TNFSF4 NM_003326 1.98 3 1087 60.1 Y Y nc Cytokine
CLEC14A NM_175060 4.34 3 1081 32.4 Y nc nc Pro-angiogenic
NRP1 NM_003873 1.30 3 1077 24.1 Y nc nc VEGFA-stimulation, endothelial cell migration
NNMT NM_006169 1.74 3 1070 28.4 Y nc nc S-adenosyl methionine, methyl donor
BMX NM_001721 3.23 3 1065 38.9 Y nc nc Transduction of VEGFA (transcript variant 2)
HMGA2 NM_003483 9.19 3 1065 29.0 Y nc nc Angiogenesis
BMX NM_203281 1.09 3 1064 38.3 Y nc nc Transduction of VEGFA (transcript variant 1)
SULT1B1 NM_014465 2.10 3 1053 23.9 Y nc nc RORA mediated inflammation
TRIM22 NM_006074 6.48 3 1051 19.2 Y nc nc Endothelial cell activation and inflammation
HTR1B NM_000863 5.76 3 1050 21.3 Y nc nc Angiogenesis
IL1RL1 NM_003856 2.64 3 1049 12.8 Y nc nc Angiogenesis and vascular permeability
BCL6B NM_181844 1.39 3 1048 13.3 Y nc nc Mediates VEGFR-signaling in angiogenesis
TNFRSF10D NM_003840 4.54 3 1048 10.7 Y Y nc TNF-superfamily member
([) Increased, (Y) decreased, (nc) no change conferred by TSA stimulation, (FC) fold change, (CpGm) CpG methylation.
Deacetylation by HDAC inhibition
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We hypothesized that inhibition of EP300/CREBBP activity
was associated with gene suppression mediated by HDAC in-
hibition. Consistent with this idea, C646 alleviates TSA-dependent
suppression of BMX and PALMD as well as IL6 and NOS3 (Fig. 3D).
The expression of STAC2 is dependent on TSA-mediated histone
acetylation. We show that C646 attenuated TSA-dependent ex-
pression of STAC2, consistent with the idea that EP300/CREBBP
activity is required for gene expression (Fig. 3E). ChIPwas performed
to determine whether TSA changes the interaction of CREBBP on
target genes. The release of CREBBP binding on BMX and IL6 genes
was consistent with histone deacetylation by TSA (Fig. 3F). We also
examined the interaction of CREBBP on the STAC2 gene and ob-
served no significant change in CREBBP binding on the promoter.
While we show a role for EP300/CREBBP gene regulation following
HDAC inhibition, the suppression of CCL2 was not alleviated by
C646 (Fig. 3G). These results indicate a role for EP300/CREBBP
regulation of gene expression mediated by HDAC inhibition.
Intersecting data sets identify deacetylation
Following the discovery of genome-wide deacetylation in our
data, we questioned why deacetylation had not been previously
reported. We searched the public domain and identified ChIP-seq
data sets for human CD4+ T-cells stimulated by the HDAC inhib-
itors, TSA and sodium butyrate (Bu) (Wang et al. 2009). While this
study showed HDAC inhibition was associated with gene expres-
sion mediated by increased acetylation, the study did not report
histone deacetylation. First we examined TSA-stimulated HAECs
and show a tight correlation for gene expression andH3K9/14ac at
promoters (Fig. 4A). Next we reexamined ChIP-seq data derived
from CD4+ T-cells to show a strong association for increased Pol II
binding (used as a proxy for changes in gene expression) and in-
creased H3K9ac in the top 500 up-regulated genes (Fig. 4B). We
observed reduced Pol II binding associated with histone deacety-
lation in the top 500 genes with the greatest reductions in ex-
pression. Furthermore, MA plots of the H3K9ac data at 2 h (Sup-
plemental Fig. 6A) and 8 h (Supplemental Fig. 6B) show a similar
pattern of histone deacetylation that was consistent with our own
analyses of primary human vascular endothelial cells. Comparison
of known HAT binding sites in TSA/Bu-stimulated CD4+ T-cells
show deacetylation at gene promoters (FDR Q-value < 0.05) asso-
ciated with EP300 and CREBBP binding, as well as PCAF and MOF
(Fig. 4C). Taken together, these results indicate that highly acety-
lated regions of the genome are subject to deacetylation and the
release of HAT binding at promoters.
SAHA confers broad deacetylation and expression changes
Bearing structural similarity to TSA, SAHAwas the first hydroxamic
acid approved by the US FDA for clinical trials (Mann et al. 2007).
Like TSA, SAHA stimulation results in increased histone acetyla-
tion (Supplemental Fig. 6C). We observed a strong correlation in
gene expression changes (Pearson’s r = 0.99) (Supplemental Fig. 6D)
and H3K9/14ac at gene promoters for TSA and SAHA (Pearson’s r =
0.99) (Supplemental Fig. 6E). Conversely, we found differences in
H3K4me3 signals in response to the hydroxamic acids (Supple-
mental Fig. 6F). We examined the distribution of peaks and found
similar changes in histone acetylation for both SAHA and TSA
(Supplemental Fig. 7A). Like TSA-stimulated cells, ChIP-seq analyses
of SAHA-stimulated HAECs showed genome-wide gains and losses
in H3K9/14ac, and genomic regions with a high level of acetyla-
tion before SAHA stimulation were subject to histone deacetylation
(Supplemental Fig. 7B). SAHA also conferred changes in H3K9/14ac
and H3K4me3 at specific features of the genome comparable to
deacetylation changes mediated by TSA (Supplemental Fig. 7C).
Pathway analysis confirmed common gene expression
changes to cytoskeletal remodeling, chemokine pathways, trans-
lation, and development for both HDAC inhibitors (Supplemental
Table 3). Given that a key feature of the TSA data was the strong
correlation between histonemodification and gene expression, we
Table 4. HDAC inhibition alters coregulators of gene transcription
Gene expression changes Modification at TSS Name and description
Gene Accession Adj. P-value FC H3K9/14ac H3K4me3 CpGm Description
HDAC5 NM_001015053 2.03 3 1017 +5.21 Y [ nc Histone deacetylase 5
HDAC3 NM_003883 6.02 3 1023 +4.96 Y [ nc Histone deacetylase 3
HDAC11 NM_024827 2.38 3 104 +2.33 Y [ nc Histone deacetylase 11
HDAC1 NM_004964 1.59 3 106 +2.11 Y [ nc Histone deacetylase 1
HDAC7 NM_015401 1.64 3 107 2.58 Y nc nc Histone deacetylase 7
KAT2A NM_021078 4.94 3 104 0.95 Y nc nc Histone acetyltransferase 2A
KAT2B NM_003884 2.29 3 102 0.75 Y nc nc Histone acetyltransferase 2B
KAT5 NM_006388 9.34 3 103 2.91 Y nc nc Histone acetyltransferase 5
KAT6B NM_012330 7.67 3 108 2.91 Y nc nc Histone acetyltransferase 6B
CREBBP NM_001079846 5.11 3 1010 2.99 Y nc nc CREB binding protein
EP300 NM_001429 1.12 3 103 1.68 Y nc nc E1A binding protein p300
NCOA6 NM_014071 8.83 3 107 2.25 Y nc nc Nuclear receptor coactivator 6
NCOA5 NM_020967 1.93 3 107 2.39 Y nc nc Nuclear receptor coactivator 5
NCOA2 NM_006540 1.82 3 105 2.62 Y nc nc Nuclear receptor coactivator 2
SMYD2 NM_020197 2.69 3 1011 3.56 Y nc nc SMYD family member 2
SMYD3 NM_001167740 1.46 3 107 +2.69 Y nc nc SMYD family member 3
SMYD5 NM_006062 3.74 3 107 2.53 Y nc nc SMYD family member 5
SUV39H1 NM_003173 5.45 3 1011 3.81 Y nc nc Suppressor of variegation 3-9 homolog 1
SUV420H1 NM_017635 6.29 3 104 2.27 Y nc nc Suppressor of variegation 4-20 homolog 1
NSD1 NM_172349 7.43 3 1016 3.78 Y nc nc Nuclear receptor binding SET domain protein 1
SETD1B NM_015048 2.71 3 1014 4.26 Y nc nc SET domain containing 1B
SETD7 NM_030648 4.16 3 1028 6.06 Y nc nc SET domain containing 7
([) Increased, (Y) decreased, (nc) no change conferred by TSA stimulation, (FC) fold change, (CpGm) CpG methylation.
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Figure 3. Loss of EP300/CREBBP HATs at gene promoters is associated with histone deacetylation. (A) GSEA identifies changes in transcription factor
binding at deacetylated gene promoters using the ENCODE ChIP-seq collection of various transcription and coregulatory factors and chromatin-asso-
ciated proteins (TFBS). A negative normalized enrichment score (NES) shows deacetylated gene sets, while a positive NES score indicates gene sets
associated with histone acetylation. All gene sets are NOM P-value < 0.05 and FDR Q-value < 0.05 according to the standard GSEA output. Yellow bars
indicate corresponding changes in gene expression of the DNA or chromatin-bound factors in TSA-stimulated HAECs (adjusted P < 0.05). Numbers
following the protein name represent the cell line and have been defined in the Supplemental Methods. (B) GSEA plot showing an association of EP300-
bound genes associated with histone deacetylation in response to TSA. Genes are ranked by changes in H3K9/14ac. (C ) Gene expression changes of
HAECs exposed to the C646 EP300/CREBBP inhibitor compared to DMSO control, determined by qRT-PCR. Genes are divided into three groups based on
EP300/CREBBP-dependent regulation. The first group comprises expressed genes dependent on EP300/CREBBP; the second group is EP300/CREBBP-
independent genes; and the third group is suppressed genes dependent on EP300/CREBBP. All data, n = 4, except for IL8 and IRS2, n = 3. (D,E) qRT-PCR
was performed in TSA-stimulated HAECs (500 nM, 12 h), C646 (20 mM, 15 h), and a combination of both C646 and TSA (C646: 20 mM, 15 h; TSA: 500
nM, 12 h). All changes in expression (TSA, C646, TSA + C646) are relative to the DMSO control. Gene expression was determined by normalizing against
HPRT1. TSA-stimulated changes in gene expression are shown for genes with promoters associated with decreased (D) and increased (E) histone acet-
ylation. (F) ChIP analysis was performed using anti-CREBBP antibody in TSA-stimulated HAECs (TSA: 500 nM for 12 h). (G) TSA-dependent changes in gene
expression regulated by the C646 EP300/CREBBP inhibitor. Error bars represent SEM. For DMSO-, TSA-, and C646-treated cells, n = 4. For TSA + C646
treated cells, n = 3. For CREBBP ChIP, n = 3. (*) P < 0.05, (**) P < 0.005, (***) P < 0.0005, (****) P < 0.0001, (#) P < 0.06, unpaired t-test.
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used Fisher’s exact test to determine if this was indeed consistent
for SAHA. The results show a striking resemblance toTSA-stimulated
cells, with SAHA inducing increased H3K9/14ac and H3K4me3
tightly associated with increased gene expression (odds ratios of
2.99 and 2.27, respectively) (Supplemental Table 4). Reduced gene
expression was correlated with loss of H3K9/14ac and H3K4me3
(odds ratios of 1.50 and 2.54, respectively). This close relationship
between the SAHA and TSA data sets was also evident for gene ex-
pression. We observed clustering of deacetylated promoters at
down-regulated genes (Fig. 4D). SAHA was also associated with in-
creased H3K9/14ac and H3K4me3 at genes with the greatest in-
crease in gene expression (Fig. 4E), whereas reduced gene expression
was associated with deacetylation (Fig. 4F). Furthermore, SAHA in-
creased histone acetylation of genes associated with REST and
SUZ12 and reduced acetylation of genes associated with binding of
BRCA1 and the HATs EP300 and KAT2A (Supplemental Fig. 7D).
Consistent with our earlier observations, we found that deacety-
lated genes were enriched for EP300 (Supplemental Fig. 7E). This
further highlights similarity in the response to TSA and SAHA
stimulation in HAECs. To visualize differential acetylation impli-
cated in gene expression, we examined genes important in vascular
endothelial function. Increased expression of STC1 was associated
with promoter H3K9/14ac following TSA and SAHA stimulation
(Fig. 5A). In contrast, reduced CCL2 gene expression by TSA and
SAHA was not linked with reduced H3K9/14ac (Fig. 5B). Further-
more, we found deacetylation of H3K9/14 at the promoters of
down-regulated genes IL6 (Fig. 5C) and BMX (Fig. 5D).
Proof of concept in vivo: deacetylation by HDAC inhibition
Having demonstrated ex vivo that pharmacological HDAC in-
hibition confers histone deacetylation, we investigated the phe-
nomenon in vivo. We hypothesized that vascular tissue would
show the characteristics of histone deacetylation inmice. As shown
in Figure 6A, TSA administration did not confer any significant
changes to heart mass (control 1036 4mg versus TSA 1076 5mg).
To study cardiac function, noninvasive echocardiography was
used to measure left ventricular (LV) dimensions end-diastole and
end-systole, as well as LV fractional shortening (FS). We found no
significant differences in cardiac performance between control
Figure 4. Genome-wide deacetylation using HDAC inhibitors. (A) Heat map showing gene expression (adjusted P < 0.05) and corresponding histone
acetylation changes. HAECs were stimulated with 500 nM TSA for 12 h, and the corresponding changes in H3K9/14ac (ChIP-seq) at the promoter region
were intersected with gene expression (mRNA-seq). (Red) Increases in gene expression and histone acetylation; (blue) corresponding decreases. (B) Heat
map of changes in gene expression, based on Pol II ChIP-seq, in CD4+ T-cells stimulated with 100 ng/mL TSA and 2 mM sodium butyrate for 2 h, and
corresponding changes in H3K9ac (at 2 and 8 h). Data derived from GEO (Series ID: GSE15735). (C ) Normalized enrichment scores derived from GSEA
showing the association of HATs in native CD4+ T-cells (determined by ChIP-seq) and changes in acetylation following 8 h stimulation with 100 ng/mL TSA
and 2 mM sodium butyrate. (D) Heat map showing changes in gene expression (adjusted P < 0.05) in SAHA-stimulated HAECs (2 mM, 12 h) and
corresponding changes in H3K9/14ac at gene promoters. (E,F) Gene expression changes are associated with H3K9/14acmodification in SAHA-stimulated
HAECs. Genes were ranked based on expression derived frommRNA-seq analysis. (For example, the top ‘‘10’’ genes are shown followed by the top ‘‘20’’
genes and so on [adjusted P < 0.05].) The largest category represents ‘‘all’’ genes and ‘‘nc’’ refers to no change in gene expression.
Figure 5. HDAC inhibition by SAHA and TSA. H3K9/14ac at promoters of genes implicated in vascular endothelial function in response to TSA and
SAHA stimulation are shown. (A) Increased STC1 gene expression was associated with promoter acetylation. (B) Reduced CCL2 gene expression was not
associated with changes in histone acetylation. Reduced IL6 (C ) and BMX (D) gene expression were associated with histone deacetylation. H3K9/14ac
profiles shown are representative of three independent experiments. Kernel density estimation bandwidth: 200.
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and TSA-injected mice, measured by LVDd (left ventricular di-
mension at diastole 4.10 6 0.06 mm versus 3.98 6 0.13 mm) and
FS (fractional shortening 38 6 2% versus 33 6 2%). Consistent
with our data for primary human cells, ChIP-seq revealed that the
LV in mice was also subject to broad histone acetylation and
deacetylation (Fig. 6B). Changes in H3K9/14ac signals were com-
parable at promoters andweremore likely to occur at the gene body
than at intergenic regions (Fig. 6C).We examined thedistributionof
H3K9/14ac in specific regions of the mouse genome, namely pro-
moters, coding exons, exons, introns, 39UTR, and 59UTR, as well as
intergenic regions. Histone acetylation changes were more likely to
occur within a gene than outside a gene (Fig. 6D). In summary, the
experimental results presented using pharmacological HDAC in-
hibitors show histone acetylation and deacetylation using ex vivo
and in vivo models.
Discussion
When, in 1990, the group of Minoru Yoshida reported that
trichostatin A inhibits HDAC activity, the significance of this
original finding was probably underappreciated (Yoshida et al.
1990). Since this report, more than 3000 articles have been pub-
lished on TSA, and 30 years later we have gained considerable
insight into chromosome and histone metabolism as well as the
function of HDAC enzymes using genetic approaches. While there
are many roles for histone deacetylases in development and
physiology, interest has recently intensified with the introduction
of HDAC inhibitors to the clinic (Haberland et al. 2009). Whereas
the impact of HDAC inhibition on chromatin structure and func-
tion is unequivocal, themode of action remains poorly understood.
In this study we reveal important clues for understanding HDAC
inhibition in vascular cells. The large-scale experimental results
challenge traditional views that increased acetylation is the pre-
dominant event driving gene expression changes, and instead, TSA
and SAHA induce genome-wide deacetylation. Our findings are
particularly novel for three reasons. First, to our knowledge there are
no data showing genome-wide changes comprehensively analyzed
in this fashion using ex vivo and in vivo models. Second, we de-
scribe deacetylation associated with reduced EP300/CREBBP bind-
ing as a novel regulatory mechanism. Third, and most important
clinically, our study is the first to demonstrate deacetylation of
primary vascular cells by the proto-typical HDAC inhibitor, TSA as
well as SAHA, a drug recently approved by the FDA. Taken together,
the data presented argue the long-held views of HDAC inhibition
may be subject to more flexibility than previously thought.
Complexity of histone modification changes
Our findings indicate TSA and SAHA significantly alter the ex-
pression of ;30% of gene transcripts. While this is in accordance
with previous findings using ENCODE arrays (Rada-Iglesias et al.
2007), it is not known whether deacetylation reduces gene ex-
pression (Peart et al. 2005). Almost 50% of deacetylation events
and 10% of acetylation events occur within 2.5 kb of the tran-
scription start sites. We have shown that changes in histone acet-
ylation alone do not necessarily correlate with differential gene
expression. Our findings are different from observations which
have typically focused on a subset of genes (Suzuki et al. 2002).
While our efforts to characterize chromatin maps demonstrate
deacetylation by HDAC inhibition, it was the reexamination of
independent data sets that further emphasized the generality of
our findings (Wang et al. 2009). Indeed, intersecting ENCODE
transcription factor binding with our own data exposed important
insights into the mechanisms that regulate gene expression. As for
CpG methylation content, reduced gene expression was clearly
associated with histone deacetylation and most likely to occur at
LCPs rather than HCPs. High CpG promoters were associated with
increased gene expression. The function of CpG methylation at
target genes responsive to HDAC inhibition is poorly understood,
and one explanation is that sites of histone acetylation are pro-
tected from HDAC inhibition at HCPs. Recent studies have shown
that H3K4me3 and H3K79me1 are more predictive for gene ac-
tivity at LCPs, whereas H3K27ac and H4K20me1 are informative
for HCPs (Karlic et al. 2010). We have shown TSA-stimulated cells
undergo increased gene expression at HCPs, suggesting that his-
tone acetylation does not solely drive increased gene expression.
While the explanation for differences in acetylation and deacety-
lation events at LCPs and HCPs is unclear, we hypothesize that
other chromatin modifications are more predictive of gene expres-
sion change than DNA methylation alone.
Histone deacetylation of EP300/CREBBP target genes
The function of regulatory proteins such as histone acetyl-
transferases may be relevant to regulating gene expression patterns
implicated in endothelial dysfunction and vascular inflammation.
Central to this postulate was the reduced expression of EP300 and
CREBBP genes by TSA. The EP300/CREBBP inhibitor C646 could
Figure 6. HDAC inhibition confers H3K9/14 acetylation and deacety-
lation in the heart. C57BL/6 male mice were injected subcutaneously with
TSA twice daily over a 4-wk period. (A) Image of hearts from control and
TSA-injected mice. (B) Ideogram of differential H3K9/14ac regions for
mouse (mm9) genome. (C ) H3K9/14ac changes in mouse left ventricle
calculated and shown as the total number of histone acetylation and
deacetylation sites at intergenic regions, gene body, and promoter re-
gions. (D) Distribution of H3K9/14 acetylation and deacetylation shown
by genomic feature using Fisher’s exact test, represented as the log2 odds
ratio. Error bars represent 95% confidence intervals. Feature annotation is
described in the Methods.
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attenuate changesmediated byHDAC inhibition. For example, C646
prevented TSA-dependent suppression of cytokine genes regulated
by CREBBP binding. Based on these findings, we propose twomodes
of transcriptional regulation. First, TSA suppresses IL6 gene expres-
sion by targeting promoter deacetylation and reduced EP300/
CREBBP binding. This mode of gene suppression is consistent with
observations that C646 alleviates TSA-mediated changes. Second, we
believe this is distinguishable in mechanism from that of CCL2 gene
regulation because TSA reduced gene expression despite treatment
with C646 inhibitor. Whereas IL6 is suppressed by deacetylation,
CCL2 expression is independent of deacetylation by EP300/CREBBP.
Our data show that EP300/CREBBP physically interacts with gene
promoters and leads to deacetylation by HDAC inhibition. With
implications for regulation of gene transcription, we demonstrate
EP300/CREBBP-dependent genes usingC646 in TSA-stimulated cells.
While EP300/CREBBP has been documented to regulate gene ex-
pression by HAT activity (Li et al. 1998, 1999), it is not clear which
lysine residues other than K9/K14 are targeted in vivo. Further ex-
periments are needed to clarify the extent of histone deacetylation by
HDAC inhibition. While we have shown EP300/CREBBP binding at
target genes, multiple changes mediated by pharmacological HDAC
inhibition could be working in combination or independently with
other transcription factors to regulate gene expression.
Distinct deacetylation signals in reanalyzed data
As for the position of genome-wide changes, reanalysis of in-
dependent data shows deacetylation at genes with high initial levels
of HAT binding in CD4+ T-cells (Wang et al. 2009). Recent experi-
mental evidence suggests HATs can be auto-acetylated, and these
complexes can be recruited to many classes of DNA binding tran-
scription factors (Blanco-Garcia et al. 2009; Hansson et al. 2009;
Albaugh et al. 2011; Yang et al. 2012a,b). Indeed, HDAC inhibition
is implicated in EP300 hyperacetylation, and its auto-acetylation has
been shown to increase protein stability and prevent proteasomal
degradation (Kim et al. 2010; Jain et al. 2012). While it is possible
that acetylation changes of nonhistone proteins alter protein
degradation as well as recruitment and binding to promoters, this
remains an area for further investigation. With respect to pharma-
cological HDAC inhibition, changes in HAT binding and function
only partly explain deacetylation. HATs and HDACs have been
shown to interact and regulate the activity of YY1 directly by
changing its acetylation status (Yao et al. 2001). Since transcriptional
repression can exert an equally fundamental role in gene regulation
as transcriptional activation, we hypothesize that changes in the
acetylation status of DNA-binding factors such as YY1 can alter their
function. Although many transcription factors and chromatin-as-
sociated proteins were associated with deacetylation, we identified
only two that were associated with increased acetylation: REST,
which is involved inneuronal gene repression outside the brain, and
SUZ12, a critical component of the polycomb repressor complex 2,
which mediates H3K27me3 and gene silencing (Coulson 2005;
Margueron and Reinberg 2011). Since RESTand SUZ12 participate in
suppressive gene events (Montgomery et al. 2005; Nakagawa et al.
2006), further experiments are needed to clarify their role in tran-
scription subject to HDAC inhibition.
Control of vascular function
As critical regulators of vascular wall homeostasis and signaling to
inflammatory cells, endothelial cell dysfunction is strongly asso-
ciated with inflammation in diabetes and associated vascular
complications including cardiovascular disease. Pathways relevant
to angiogenesis and inflammation, including changes in chemo-
kine and cytokine related pathways, were identified in cells stim-
ulated by HDAC inhibition. For example, reduced expression of
BMX, which is implicated in VEGFA transduction, PALMD (vas-
cular development), IL6 (cytokine and inflammation), and BRG1
(chromatin remodeling), as well as NOS3 (VEGFA-induced angio-
genesis) was correlatedwith EP300/CREBBP activity at these genes.
While HDAC inhibitors are also known to induce pleiotropic ef-
fects on HATs and other nonhistone proteins (Choudhary et al.
2009), we propose that gene expression changes are mediated by
the direct loss of EP300/CREBBP-dependent acetylation.
HDAC7 is a member of the class II HDACs and is believed to
control endothelial cell growth in the vasculature (Margariti et al.
2010). Our studies showed that HDAC inhibitors suppress the
expression of HDAC7 in vascular endothelial cells. Genetic de-
letion of mouse Hdac7 causes embryonic lethality because of fail-
ure in endothelial cell interactions that result in dilatation and
blood vessel rupture (Chang et al. 2006). In the Hdac7 null mouse,
vascular disruption is accompanied with elevated expression of
matrixmetalloproteinase 10 (Mmp10), which regulates endothelial
cell interactions conferred by increased activity of the transcrip-
tional coactivator, MEF2A. Pathological expression of matrix
metalloproteinase and extracellular remodeling are implicated in
cardiovascular disease. While the mechanism of MEF2A gene reg-
ulation remains uncharacterized, our data showed that TSA-stim-
ulated HAECs suppressed HDAC7 expression, which is inversely
correlated with MEF2A expression in the heart. Because HDAC
inhibitors such as SAHA have entered clinical trials, it is important
to determine the true physiological properties.While it is clear that
pharmacological inhibitors can work in several ways that target
chromatin and nonchromatin substrates, the results presented
here show that the chromatin template is subject to deacetylation
of histone lysine residues. Equally surprising is the efficacy of
HDAC inhibitors in pathological models of cardiac failure. In the
myocardium, nonhistone substrates are targets of intracellular
signaling pathways that are regulated by HDAC inhibition (Song
et al. 2006; Bush and McKinsey 2010). Expression of structural
proteins in the mouse myocardium is dependent on MEF2 family
transcription factors (Lin et al. 1997) which interact with EP300/
CREBBP for functionality (Eckner et al. 1996). Indeed, impaired
activity of MEF2 proteins in the heart is associated with altered
expression of contractile proteins in Ep300 null embryos (Yao et al.
1998). Given the observations reported here, we hypothesize that
the response of histone deacetylation by TSA and SAHA are not
necessarily under the control of a single pathway, but rather un-
derlie the involvement of multiple signaling events. Indeed, such
cross-coupling, whereby transcriptional changes are mediated by
the coordination of multiple signaling pathways, is observed in
Ep300 and Crebbp null animals.
Proof-of-principle: histone deacetylation in vivo
The therapeutic potential for the use of HDAC inhibitors in heart
disease is well described (Olson et al. 2006). Since treatment with
TSA blocks cardiac hypertrophy in models of preexisting heart
failure (Kook et al. 2003; Kee et al. 2006), we examined genome-
wide histone acetylation changes in preclinical models. The ra-
tionale behind these experiments was twofold. First, although
systemic TSA treatment is strongly predicted to increase histone
acetylation, to our knowledge there are no data that comprehen-
sively examine this phenomenon in vivo. Second, and more im-
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portant clinically, these experiments explore proof-of-concept,
that is, HDAC inhibition confers strong deacetylation, which is
relevant not only to the vascular endothelium and the myocar-
dium but also because pharmacological inhibitors have entered
clinical trials (Lehrman et al. 2005; Almeida et al. 2007;Mann et al.
2007). Our data highlight that the heart undergoes dramatic
changes in H3K9/14 deacetylation, which are more likely to occur
within a gene than outside a gene. Whether histone deacetylation
of EP300/CREBBP target genes is conferred in the myocardium is
a fertile area of future investigation.
Conclusions
Characterizing the vascular epigenome is important, considering
that pharmacokinetics and pharmacology of HDAC inhibitors
have been studied and largely determined by ADME properties
(absorption, distribution, metabolism, and extraction). Vascular
toxicity is critical to early drug design development or rational
drug discovery. While preclinical ADME screens provide useful
data, genome-wide studies are still limited. Given the poorly char-
acterized mechanisms regulating endothelial function and in-
flammation, our data define major roles for transcription and
coregulatory factors such as EP300/CREBBP regulating chromatin
modification. Since drug development relies on improving the
design of pharmacological inhibitors, determining the role of
chromatin and nonchromatin targets will likely require definition
of these changes to understand themechanisms of gene regulation.
The comprehensive chromatin maps described here should provide
a useful framework and resource to further understand deacetyla-
tion by HDAC inhibitors.
Methods
Cell culture
Human aortic endothelial cells purchased from Lonza were cul-
tured in endothelial cell basal growth medium-2 (EBM-2) (Lonza)
containing EGM-2 growth factors, supplements (Lonza), and 10%
heat-inactivated fetal bovine serum (FBS) (Gibco). Cells used for
the experiments were from passages 4–6. HAECs were stimulated
with 500 nM TSA or 2 mM SAHA for 12 h for all mRNA-seq and
ChIP-seq. For qRT-PCR, HAECs were exposed to 20 mM C646 for
15 h. For combined TSA andC646, cells were incubated to C646 for
3 h before stimulation with TSA for a further 12 h.
Cell viability
Cell viability following treatment with the indicated concentra-
tions of TSA for 12 h at 37°C was measured using the CellTiter96
Aqueous One Solution Cell Proliferation Assay (MTS) (Promega)
and crystal violet staining methods, as described in the Supple-
mental Material.
In vivo mouse model
C57BL/6 male mice (10–12 wk old) were injected subcutaneously
twice daily at 0.6 mg/kg/day of TSA for 4 wk, as previously de-
scribed (Chang et al. 2011). To study cardiac function, noninvasive
echocardiography was used to measure left ventricular (LV) di-
mensions end-diastole and end-systole as well as LV fractional
shortening (FS). The animals were killed and the LVs isolated and
snap-frozen immediately for downstream molecular experiments.
For gene expression, RNA isolation and cDNA synthesis were per-
formed as previously described. LVs were pooled for one ChIP
experiment with H3K9/K14 antibody (06-599, Upstate) and per-
formed as previously described (Chang et al. 2011).
Protein blotting
Immunoblotting for acetyl-H4 (06-866, Upstate), acetyl-H3K9/14
(06-599, Millipore), H3K4me1 (39297, Active Motif), H3K4me2
(7766, Abcam), H3K4me3 (07-473, Upstate), H3K9me1 (9045,
Abcam), H3K9me2 (39141, Active Motif), and H3K9me3 (8898,
Abcam) was performed using histone H3 (05-928, Upstate) as the
loading control on histones prepared under acidic conditions from
TSA-stimulated HAECs, as described in the Supplemental Material.
Inflammation studies
Monocyte adhesion assay, cytokine and chemokine release assay,
and PMA assay have been described in the SupplementalMethods.
Chromatin immunoprecipitation
Chromatin immunoprecipitation was performed according to the
manufacturer’s procedure (Upstate Biotechnology) with some
modifications. Native and TSA-stimulated HAECs and mouse left
ventricle (cut into fine pieces) were fixed for 10 min with 1%
formaldehyde. Glycine (0.125 M) solution was then added for
another 10 min. Cell pellets and left ventricle pieces were resus-
pended in sodium dodecyl (lauryl) sulfate (SDS) lysis buffer (1%
SDS, 10 mM EDTA, 50 mM Tris-HCl, pH 8.1) (Upstate) and a pro-
tease inhibitor cocktail (Roche Diagnostics GmBH). Cells and left
ventricles were sonicated to shear chromatin to 200–600 bp.
Chromatin was resuspended in ChIP dilution buffer (0.01% SDS,
1.1% Triton X-100, 1.2 mM EDTA, 16.7 mM Tris-HCl, pH 8.0, and
167 mM NaCl) (Upstate), and 20 µl of Dynabeads Protein A
(Invitrogen) were added and precleared. To the soluble chromatin
fraction, antibody (H3K9/14ac, 06-599,Millipore;H3K4me3, 39159,
Active Motif; H3K9me3, 8898, Abcam; CREBBP, sc-369, Santa Cruz
Biotechnology) was added and incubated overnight at 4°C. Im-
munoprecipitated complexes were collected with DynaMag-2
magnet (Invitrogen), washed (in the following sequence: low-salt
buffer, high-salt buffer, LiCl-containing buffer, TE buffer) and
eluted with 0.1MNaHCO3 with 1% SDS. Protein-DNA cross-links
were reversed by adding 120 mg of Proteinase K (Sigma) and in-
cubation at 62°C for 2 h. DNA was recovered using a Qiagen
MinElute column (Qiagen).
Library construction and mRNA sequencing
Total RNA was isolated with TRIzol (Invitrogen). Libraries were
prepared according to the Illumina mRNA-seq library preparation
kit (cat. #RS-100-0801). Briefly, 8 µg of total RNA was taken for
mRNA isolation using poly-T oligo-attached magnetic beads.
Poly-A mRNA was fragmented with the presence of divalent cat-
ions under elevated temperatures. The mRNA fragments were re-
verse-transcribed via SuperScript II (Invitrogen) with random
primers. The second strandwas synthesizedwith additionof RNase
H andDNA Pol I. Double-stranded complementary DNA (dscDNA)
was end-repaired, followed by 39 adenylation and ligation to
universal adapters. The ligated cDNA library was separated on a
2.0% agarose gel. Library cDNA fragments in the range of 200 bp6
10 bp were isolated by gel purification (Qiagen) and amplified
with 15 cycles of PCR. Column-purified libraries were quantified
fluorometrically and visualized by MultiNA for quality assurance.
Libraries were diluted to 10 nM and stored at20°Cprior to cluster
generation (also at a concentration of 6 pM) and 36-base se-
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quencing. Short-read sequences of 36 base pairs were generated
using Illumina Pipeline 1.4. Each sequence read was aligned with
the Burrows-Wheeler Aligner (BWA, version 0.6.1) against the hg19
RefSeq transcriptome, downloaded from UCSC (Li and Durbin
2010). The read count for each transcript was transformed into
a matrix, with transcript ID as rows and sample name as columns.
The conditions in thismatrix were compared for significance using
edgeR software (Robinson et al. 2010). Genes were determined as
significant if the Benjamini-Hochberg adjusted P < 0.05 (Benjamini
and Hochberg 1995).
Massive parallel sequencing for ChIP
ChIP-seq librarieswereprepared according to the protocols described
in the Illumina ChIP-seq library preparation kit (cat. #IP-102-1001).
Briefly, 10 ng of immunopurified DNA or genomic DNA from an
input sample was end-repaired, followed by 39 adenylation using
a Klenow fragment (39 to 59 exo minus) and ligated to universal li-
brary adapters with T-overhangs at their 39 end. Ligatedmaterialwas
separated on a 2.0% agarose gel, and fragments in the range of 250–
350 bp were excised and column-purified (Qiagen). A DNA library
was obtained by an 18-cycle PCR amplification using Phusion DNA
polymerase (10 sec 98°C, 30 sec 65°C, 30 sec 72°C) with oligonu-
cleotides complementary to Illumina sequencing adapters. Col-
umn-purified libraries were quantified fluorometrically (Qubit) and
visualized by MultiNA capillary electrophoresis (DNA 500 kit) for
quality assurance. Libraries were diluted to 10 nM and stored at
20°C prior to cluster generation at a final DNA concentration
of 6 pM. Sequencing of the first 36 nucleotides was performed on
the Genome Analyzer IIx instrument (Illumina) according to the
manufacturer’s protocols. Short-read sequences of 36base pairswere
generated using Illumina Pipeline 1.4. These short reads were
aligned with BWA (version 0.6.1) (Li and Durbin 2010) against the
hg19 human genome (hg19, GRCh37, February 2009) (HAEC
samples) and mm9 mouse genome (left ventricle) using default
parameters. Regions of interest were defined by comparing each
human ChIP sample against an input sample from the same con-
dition, and the mouse H3K9/14ac ChIP against an unstimulated
control, using MACS (version 1.4.1) software using default param-
eters (Zhang et al. 2008) with a cutoff of P = 105, except for the
human marker H3K9me3, which was compared to the first 10,000
base pairs of genes bodies in the hg19 genome (hg19, GRCh37,
February 2009). For ChIP-seq, all overlapping regions of histone
modification in the TSA-stimulated and unstimulated control cells
were merged to create a single list of regions as determined by
MACS. The number of reads occurring in these regions was de-
termined for each control and treatment replicate to generate
a matrix of read counts. Significant differences between unstimu-
lated and TSA-stimulated cells were determined by edgeR and
trimmed using mean normalization (nondifferential sequence read
count quantile threshold of 0.3, prior. n of 20, and P-value threshold
for FDR filtering for family-wise error rate control of 0.05) (Robinson
et al. 2010). Genomic regions were determined as significant if
the Benjamini-Hochberg adjusted P-value < 0.05 (Benjamini and
Hochberg 1995). Data from SAHA-stimulated cells was analyzed
usingMACS (version 1.4.1) peak calling, by comparing each sample
to the input, using default settings.
Massive parallel sequencing for DNA methylation
Genomic DNA derived from native and stimulated HAECs was
fragmented to 150–200 bp by a Diagnode sonicator and subjected
to methylated DNA enrichment using the MethylMiner kit
(ME10035, Invitrogen) in triplicate. Briefly, methylated DNA was
captured from 500 ng of fragmented genomic DNA via binding
MBD2 protein coupled to magnetic Dynabeads, which was in-
cubated for 1 hwith rotation. Themethylated fragments were then
eluted in three distinct subpopulations using 0.6 M, 1 M, and 2 M
salt elution buffers, respectively (supplied in MethylMiner kit).
Methylated DNA fragments, eluted with 2 M salt buffer, were
purified and selected for sequencing on the Illumina Genome
Analyzer. Sequencing of the first 36 nt was performed on the
Genome Analyzer IIx instrument (Illumina) according to the
manufacturer’s protocols. Short-read sequences of 36 base pairs
were generated using Illumina Pipeline 1.4. These short reads were
aligned with BWA (version 0.5.9) using default parameters (Li
and Durbin 2010) against the hg19 human genome (hg19,
GRCh37, February 2009) (HAEC samples). Regions of interest were
defined by comparing each CpG-seq sample against an input
sample from the same condition using MACS software (version
1.4.1) with default parameters (Zhang et al. 2008) with a cutoff of
P = 105. Human ChIP regions were merged for each ChIP and
the read counts summarized to create a matrix with region co-
ordinates as rows and sample names as columns. The samples in
this matrix were compared for significance using edgeR software
(Robinson et al. 2010). Genes were determined as significant if
the Benjamini-Hochberg adjusted P-value < 0.05 (Benjamini and
Hochberg 1995).
Data access
The mRNA-seq, ChIP-seq, and CpG-seq data used for this research
have been submitted to the NCBI Gene Expression Omnibus
(GEO; http://www.ncbi.nlm.nih.gov/geo/) under accession num-
ber GSE37378.
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